Loading...
ATXS logo

Astria Therapeutics, Inc.NasdaqGM:ATXS Stock Report

Market Cap US$718.1m
Share Price
US$12.58
US$13
3.2% undervalued intrinsic discount
1Y68.0%
7D1.1%
1D
Portfolio Value
​
View

Astria Therapeutics, Inc.

NasdaqGM:ATXS Stock Report

Market Cap: US$718.1m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Astria Therapeutics (ATXS) Stock Overview

A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. More details

ATXS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 84.1% below our estimate of its fair value

Revenue is forecast to grow 57.5% per year

Risk Analysis

Makes less than USD$1m in revenue ($706K)

Currently unprofitable and not forecast to become profitable over the next 3 years


ATXS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Astria Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Astria Therapeutics
Historical stock prices
Current Share PriceUS$12.58
52 Week HighUS$13.29
52 Week LowUS$3.56
Beta0.019
1 Month Change-2.86%
3 Month Change-0.16%
1 Year Change67.96%
3 Year Change-8.51%
5 Year Change-35.88%
Change since IPO-98.39%

Recent News & Updates

Seeking Alpha • Nov 30

Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold

Summary I maintain a hold rating on Astria Therapeutics with an updated $13 target price following Biocryst's announced acquisition, expecting a 90%+ chance of deal closure by Q1 2026. The investment thesis shifts from clinical catalyst to merger arbitrage, with strong strategic rationale for BCRX to acquire ATXS and minimal regulatory or financial barriers anticipated. Navenibart (STAR-0215) is viewed as a best-in-class prophylaxis agent, and the acquisition offers shareholders a liquidity event, mitigating phase 3 and competitive risks. While deal risks exist, they are considered minimal; with limited upside from current prices, I have exited my existing position. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Nov 30

Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold

Summary I maintain a hold rating on Astria Therapeutics with an updated $13 target price following Biocryst's announced acquisition, expecting a 90%+ chance of deal closure by Q1 2026. The investment thesis shifts from clinical catalyst to merger arbitrage, with strong strategic rationale for BCRX to acquire ATXS and minimal regulatory or financial barriers anticipated. Navenibart (STAR-0215) is viewed as a best-in-class prophylaxis agent, and the acquisition offers shareholders a liquidity event, mitigating phase 3 and competitive risks. While deal risks exist, they are considered minimal; with limited upside from current prices, I have exited my existing position. Read the full article on Seeking Alpha
Analysis Article • Jul 08

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Mar 13

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Feb 18

Astria Therapeutics: A High-Conviction Bet On HAE

Summary Astria Therapeutics' strong cash position and efficient spending provide a financial runway through mid-2027, reducing dilution risk and supporting pivotal trials for navenibart and STAR-0310. Navenibart, targeting hereditary angioedema, shows promising Phase 1b/2 data with a 90-95% reduction in attack rates, positioning it as a potential best-in-class treatment. STAR-0310, aimed at atopic dermatitis, leverages OX40 inhibition and YTE half-life extension technology, though it faces stiff competition and must prove differentiation. Astria's strategic focus on patient-centric dosing regimens and regulatory strength could reshape treatment landscapes, but clinical and commercial execution remains crucial for success. Read the full article on Seeking Alpha
Seeking Alpha • Nov 27

Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema

Summary Astria Therapeutics, Inc.'s STAR-0215 shows 90-96% reduction in HAE attack frequency, with a twice-a-year dosing regimen, positioning it as a transformative therapy. The company has a strong cash balance of $344 million, ensuring a runway until 2027, supporting continued development and trials. Competitive positioning is strong, with STAR-0215 outperforming existing treatments like Takhzyro and Haegarda in both efficacy and dosing convenience. Risks are minimal given the promising data, making ATXS stock a buy due to its excellent data, market potential, and upcoming catalysts. Read the full article on Seeking Alpha
Analysis Article • Nov 14

Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Astria Therapeutics...
Analysis Article • Jul 11

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jun 24

Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field

Summary Astria Therapeutics stock has fallen 40% since early 2023, but promising early data for its candidate STAR-0215 in treating HAE is helping drive analyst Buy ratings. ATXS stock has a compound called STAR-0310 in development for an immune disorder, with plans for a Phase 1a study in 2025. Despite positive early data for STAR-0215, competition in the HAE market is fierce and likely to get more crowded with promising new treatments on the horizon. An updated analysis of Astria Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Feb 04

Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout

Summary Astria Therapeutics (formerly Catabasis Pharmaceuticals) acquired Quellis Biosciences and its lead program, STAR-0215, for the treatment of hereditary angioedema (HAE) in 2021. The company has successfully completed a Phase 1 study for STAR-0215, demonstrating positive results in terms of safety, tolerability, and efficacy. Astria is now moving forward with a Phase 1b/2 study to establish proof-of-concept for STAR-0215 in HAE patients, with initial results expected in Q1 2024. The promise of HAE data in Q124 appears to have lifted the share price and allowed the company to raise funds. If the promise of upcoming is already baked into the share price, given how far behind the competition Astria is in HAE, and in atopic dermatitis with a second candidate, I would give its stock a "sell" rating. Read the full article on Seeking Alpha
Analysis Article • Dec 10

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Jul 27

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. Indeed, Astria Therapeutics...
Analysis Article • Apr 03

We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Nov 30

Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Aug 01

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Jul 15

Dr. Chris Morabito is the new medical chief of Astria Therapeutics

Astria Therapeutics (NASDAQ:ATXS) names more than 20 years of clinical development experience in rare diseases and other indications Chris Morabito, M.D., as Chief Medical Officer.  Dr. Morabito most recently served as the Chief Medical Officer at Fulcrum Therapeutics.
Seeking Alpha • Jun 30

Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition

After edasalonexent's failure last year, Catabasis Pharmaceuticals pivoted to the HAE market through the acquisition of Quellis Biosciences. The acquisition brought QLS-215, a preclinical stage monoclonal antibody with a potentially improved profile compared to prophylactic market leader Takhzyro. Much longer half-life and increased potency could result in less frequent administration and it could also improve efficacy. The HAE market is increasingly competitive with additional promising therapies in development, but if preclinical data of QLS-215 translate well into humans, Catabasis could deliver significant gains in the following years.

Shareholder Returns

ATXSUS BiotechsUS Market
7D1.1%1.2%1.6%
1Y68.0%35.9%28.5%

Return vs Industry: ATXS exceeded the US Biotechs industry which returned 27% over the past year.

Return vs Market: ATXS exceeded the US Market which returned 15% over the past year.

Price Volatility

Is ATXS's price volatile compared to industry and market?
ATXS volatility
ATXS Average Weekly Movement2.7%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: ATXS has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ATXS's weekly volatility has decreased from 10% to 3% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200878Jill Milnewww.astriatx.com

Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching.

Astria Therapeutics, Inc. Fundamentals Summary

How do Astria Therapeutics's earnings and revenue compare to its market cap?
ATXS fundamental statistics
Market capUS$718.13m
Earnings (TTM)-US$124.03m
Revenue (TTM)US$706.00k
1,017x
P/S Ratio
-5.8x
P/E Ratio

Is ATXS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ATXS income statement (TTM)
RevenueUS$706.00k
Cost of RevenueUS$0
Gross ProfitUS$706.00k
Other ExpensesUS$124.74m
Earnings-US$124.03m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-2.17
Gross Margin100.00%
Net Profit Margin-17,567.99%
Debt/Equity Ratio0%

How did ATXS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/27 09:07
End of Day Share Price 2026/01/22 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Astria Therapeutics, Inc. is covered by 1 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan WollebenCitizens JMP Securities, LLC